Merck (MRK) Cash from Investing Activities Growth (1y) (2010 - 2026)
Merck (MRK) Cash from Investing Activities Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
-16.79% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-250.17% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
21.90% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
-43.02% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-586.62% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-60.18% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
526.51% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
-76.02% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
-342.92% |
| Date | Value |
|---|
| Mar 31, 2026 |
-586.62% |
| Dec 31, 2025 |
-675.69% |
| Sep 30, 2025 |
92.64% |
| Jun 30, 2025 |
27.97% |
| Mar 31, 2025 |
-8.07% |
| Dec 31, 2024 |
-2,824.53% |
| Sep 30, 2024 |
-1,051.20% |
| Jun 30, 2024 |
90.66% |
| Mar 31, 2024 |
41.67% |
| Dec 31, 2023 |
103.03% |
| Sep 30, 2023 |
65.28% |
| Jun 30, 2023 |
-962.49% |
| Mar 31, 2023 |
-101.11% |
| Dec 31, 2022 |
85.49% |
| Sep 30, 2022 |
9.33% |
| Jun 30, 2022 |
58.97% |
| Mar 31, 2022 |
-70.99% |
| Dec 31, 2021 |
-156.53% |
| Sep 30, 2021 |
49.14% |
| Jun 30, 2021 |
-235.68% |
